Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Dose-related reduction in bupropion plasma concentrations by ritonavir.

Park J, Vousden M, Brittain C, McConn DJ, Iavarone L, Ascher J, Sutherland SM, Muir KT.

J Clin Pharmacol. 2010 Oct;50(10):1180-7. doi: 10.1177/0091270009359524. Epub 2010 May 19.

PMID:
20484617
2.

Reduced duodenal cytochrome P450 3A protein expression and catalytic activity in patients with cirrhosis.

McConn DJ 2nd, Lin YS, Mathisen TL, Blough DK, Xu Y, Hashizume T, Taylor SL, Thummel KE, Shuhart MC.

Clin Pharmacol Ther. 2009 Apr;85(4):387-93. doi: 10.1038/clpt.2008.292. Epub 2009 Feb 11.

3.

An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction.

Reese MJ, Wurm RM, Muir KT, Generaux GT, St John-Williams L, McConn DJ.

Drug Metab Dispos. 2008 Jul;36(7):1198-201. doi: 10.1124/dmd.107.020198. Epub 2008 Apr 17.

PMID:
18420781
4.

Lysosomes contribute to anomalous pharmacokinetic behavior of melanocortin-4 receptor agonists.

Gong Y, Zhao Z, McConn DJ, Beaudet B, Tallman M, Speake JD, Ignar DM, Krise JP.

Pharm Res. 2007 Jun;24(6):1138-44. Epub 2007 Mar 21.

PMID:
17373577
5.

Evidence of significant contribution from CYP3A5 to hepatic drug metabolism.

Huang W, Lin YS, McConn DJ 2nd, Calamia JC, Totah RA, Isoherranen N, Glodowski M, Thummel KE.

Drug Metab Dispos. 2004 Dec;32(12):1434-45. Epub 2004 Sep 21.

PMID:
15383492
6.

Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs.

McConn DJ 2nd, Lin YS, Allen K, Kunze KL, Thummel KE.

Drug Metab Dispos. 2004 Oct;32(10):1083-91.

PMID:
15377640

Supplemental Content

Loading ...
Support Center